Neutrophil-mediated delivery of nanotherapeutics across blood vessel barrier
Neutrophil-mediated delivery of nanotherapeutics across blood vessel barrier
复制标题
DOI：
10.4155/tde-2017-0081
复制
发表时间：
2018-01-01
影响因子：
4.2
通讯作者：
Wang, Zhenjia
中科院分区：
文献类型：
--
作者：
Dong, Xinyue;Chu, Dafeng;Wang, Zhenjia
纳米治疗药物是一种载药纳米颗粒，与游离药物相比，具有组织靶向性、长循环、低毒性等特点。位于血管内腔的内皮细胞是抑制纳米治疗剂的组织沉积的屏障。中性粒细胞是一种白色血细胞，在炎症过程中穿过内皮细胞。有一个新兴的概念，即原位靶向中性粒细胞允许将纳米治疗剂递送到疾病部位的深层组织中。在这里，我们总结了通过中性粒细胞浸润将纳米治疗药物递送到炎症组织或肿瘤微环境的最新进展。这些研究将把目前的纳米医学范式转变为生物学驱动的纳米治疗设计。
Nanotherapeutics, nanoparticles (NPs) loaded with drugs, show the ability of tissue targeting, long circulation and low toxicity compared with free drugs. Endothelium lying the lumen of a blood vessel is a barrier to restrain tissue deposition of nanotherapeutics. Neutrophils, a type of white blood cells, migrate across endothelium during inflammation. There is an emerging concept that in situ targeting of neutrophils allows delivery of nanotherapeutics into deep tissues at disease sites. Here we summarize the recent advances in delivery of nanotherapeutics to inflammatory tissues or tumor microenvironments via neutrophil infiltration. The studies would shift the current paradigm of nanomedicine to biology-driven design of nanotherapeutics.